Osteopontin is a marker for cancer aggressiveness and patient survival

BACKGROUND: Only a fraction of molecular cancer markers identified in the scientific literature have found clinical use. Specifically, few predictors of invasiveness are established in diagnostics. Meta-analysis is a valuable tool for biomarker validation. Here, we evaluate Osteopontin as a marker f...

Descripción completa

Detalles Bibliográficos
Autores principales: Weber, G F, Lett, G S, Haubein, N C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966627/
https://www.ncbi.nlm.nih.gov/pubmed/20823889
http://dx.doi.org/10.1038/sj.bjc.6605834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966627/
https://www.ncbi.nlm.nih.gov/pubmed/20823889
http://dx.doi.org/10.1038/sj.bjc.6605834

Ejemplares similares